119 related articles for article (PubMed ID: 12886030)
1. Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction.
Villalobos MA; De La Cruz JP; Escalante R; Arrebola MM; Guerrero A; Sánchez de la Cuesta F
Pharmacology; 2003 Sep; 69(1):44-50. PubMed ID: 12886030
[TBL] [Abstract][Full Text] [Related]
2. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
[TBL] [Abstract][Full Text] [Related]
3. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes.
De La Cruz JP; Moreno A; Ruiz-Ruiz MI; García Campos J; Sánchez de la Cuesta F
Eur J Pharmacol; 1998 May; 350(1):81-5. PubMed ID: 9683018
[TBL] [Abstract][Full Text] [Related]
4. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor.
Gryglewski RJ; Szczeklik A; Korbut R; Swies J; Musiał J; Krzanowski M; Maga P
Wien Klin Wochenschr; 1995; 107(9):283-9. PubMed ID: 7778318
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
Sincholle D; Coquelet C; Bonne C
Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
Menys VC; Davies JA
Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
[TBL] [Abstract][Full Text] [Related]
8. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
9. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
10. Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man.
Rosenkranz B; Fischer C; Meese CO; Frölich JC
Br J Clin Pharmacol; 1986 Mar; 21(3):309-17. PubMed ID: 3083851
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of thromboxane B2 in incubates of dog platelet-rich plasma with arachidonic acid and its inhibition by different drugs.
Chignard M; Vargaftig BB; Sors H; Dray F
Biochem Biophys Res Commun; 1978 Dec; 85(4):1631-9. PubMed ID: 743319
[No Abstract] [Full Text] [Related]
12. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
13. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
14. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
15. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
16. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
Carter AJ; Heptinstall S
Thromb Haemost; 1985 Oct; 54(3):612-6. PubMed ID: 3937261
[TBL] [Abstract][Full Text] [Related]
18. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
19. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
20. Effects of mitoxantrone and bisantrene on platelet aggregation and prostaglandin/thromboxane biosynthesis in vitro.
Frank P; Novak RF
Anticancer Res; 1986; 6(5):941-7. PubMed ID: 3467648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
